Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment III Trial Revisited: Objective...

Area of Science:

• Neuroscience
• Biomarkers
• Traumatic Brain Injury Research

Background:

• Traumatic brain injury (TBI) classification often relies on broad measures like Glasgow Coma Scale (GCS) and Glasgow Outcome Scale-Extended (GOS-E).
• These measures may not capture subtle TBI recovery changes, hindering targeted therapeutic development.
• Serum biomarkers like GFAP and UCH-L1, along with lesion volume, offer potential for refined TBI classification.

Purpose of the Study:

• To investigate if improved TBI classification using serum biomarkers (GFAP, UCH-L1) and CT-assessed lesion volume can identify progesterone treatment responders.
• To evaluate the correlation between these advanced metrics and traditional injury severity scores (Rotterdam Score).
• To determine if progesterone treatment shows differential effects based on these refined classifications.

Main Methods:

• Post hoc analysis of the ProTECT III trial data.
• Quantification of brain lesion volumes using the Brain Lesion Analysis and Segmentation Tool for CT.
• Classification of patients into true-positive and true-negative groups based on lesion volume thresholds.
• Correlation analyses between lesion volume, GFAP/UCH-L1 levels, and Rotterdam Scores.
• Welch's t-test to compare biomarker levels and treatment effects between groups.

Main Results:

• Significantly higher GFAP and UCH-L1 levels were observed in true-positive TBI cases with low to medium lesion volumes.
• Only UCH-L1 showed a difference between progesterone and placebo groups at 48 hours.
• Both biomarkers and lesion volume correlated with the Rotterdam Score in the true-positive group.
• No significant sex-specific or treatment-related differences in response were identified.

Conclusions:

• Elevated GFAP and UCH-L1 levels confirm their utility as biomarkers for TBI detection and outcome prediction.
• Despite enhanced classification via CT imaging and biomarkers, a specific subset of progesterone responders was not identified.
• More precise injury classification methods are necessary for developing effective TBI therapeutics, as current advanced metrics did not outperform traditional ones.